Most interventional cardiologists would agree that the contemporary outcomes of percutaneous coronary intervention (PCI) are so respectable not only because of important developments in stent technologies, but also as the consequence of remarkable progress in antithrombotic pharmacotherapy1. The landscape of antithrombotic drugs for PCI is quite extensive, with thousands of potential strategic permutations based on drug choice, timing of administration, dose and prescribed duration. It is fair to admit that this abundance represents a clinical opportunity but also a threat when it comes to determining which of the disparate…